JB Chemicals & Pharmaceuticals (506943) Q3 25/26 earnings summary

Executive summary

• Q3 FY26 revenues grew 11% year-on-year to INR 1,065 crores, with net profit up 22% to INR 198 crores and operating EBITDA up 13% to INR 305 crores; domestic and international businesses outperformed their respective markets, led by chronic therapies and flagship brands.

• Gross margins expanded by 200 basis points to 69.1%, driven by a favorable product mix, price improvements, and stable raw material costs.

• Focus on cost optimization, operational efficiencies, and scaling CDMO contributed to improved operating margins and future growth positioning.

• Unaudited standalone and consolidated financial results for Q3 and 9M FY26 were reviewed and approved, with no material misstatements identified.

• Priorities include strengthening flagship brands, accelerating chronic therapy growth, and building organizational resilience.

Financial highlights

• Q3 FY26 revenue reached INR 1,065 crores, up 11% YoY; net profit was INR 198 crores, up 22% YoY; operating EBITDA margin improved to 28.7%.

• Gross margins improved to 69.1% in Q3 FY26 (up 200 bps YoY).

• Other income rose to INR 18 crores in Q3 FY26 due to treasury income after debt repayment.

• Depreciation was stable at INR 41 crores.

• Earnings per share (consolidated, basic) for Q3 FY26 was ₹12.63, up from ₹10.46 in Q3 FY25.

Outlook and guidance

• Guidance for operating margins remains at 27-29% for FY26, with gross margins guided to remain in the 60-69% range.

• Domestic business expected to continue outperforming the market by 200-300 basis points, with full-year growth in the 11-12% range.

• International business expected to end the year with high single-digit growth, with Q4 performance mirroring Q3.

• CDMO segment expected to grow 10-12% in FY27, with sales momentum continuing into Q4 FY26.

• The company continues to monitor regulatory changes, including new Labour Codes, and will adjust financial reporting as needed.